Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) generates news that spans biotechnology, clinical development, and commercialization of autologous stem cell therapy for ischemic disease. The company’s updates frequently center on its VesCell (ACP-01) platform, a patient-derived blood-based stem cell therapy that Hemostemix reports has been studied in multiple clinical trials for peripheral arterial disease, chronic limb threatening ischemia, cardiomyopathies, congestive heart failure, angina, total body ischemia, and vascular dementia.
Investors following HMTXF news can expect regular announcements on clinical milestones, regulatory interactions, and physician-led initiatives. Hemostemix has reported the completion of a Phase II clinical trial in chronic limb threatening ischemia, publication of results in peer-reviewed journals, and presentations of long-term outcomes such as limb preservation, wound healing, and mortality data in severe ischemic patient populations. News items also describe plans for a basket protocol Phase I trial in ischemia-related conditions and a scheduled FDA Pre-IND meeting to review the company’s proposed trial design and regulatory pathway.
Corporate developments are another recurring theme in Hemostemix’s news flow. The company issues releases on non-brokered private placements, stock option grants, and capital raises intended to fund regulatory, clinical, and commercialization activities for ACP-01. It also reports on strategic moves such as a clinic roll-up strategy, including letters of intent to acquire cardiology practices that have experience treating patients with ACP-01, as well as the build-out of patient care and clinical operations roles.
Sector-specific coverage includes Hemostemix’s participation in conferences focused on wound healing, diabetic limb salvage, and regenerative medicine, where the company highlights its CLTI and cardiovascular data. For readers tracking HMTXF, this news page offers a consolidated view of scientific, regulatory, financial, and operational updates related to Hemostemix’s autologous stem cell therapy platform.
Hemostemix (HMTXF) has announced a Phase 1 clinical trial for treating Vascular Dementia with ACP-01, targeting up to 100 patients. Each patient will pay USD $37,000 for the treatment, potentially generating USD $3.7M (CAD $5.36M) in revenue.
The trial will evaluate the safety, tolerability, and preliminary efficacy of intrathecal ACP-01 injection directly into cerebrospinal fluid. Primary endpoints include safety assessment and ACP-01 delivery feasibility, while secondary endpoints focus on cognitive function, dementia rating, and quality of life measurements.
The study will utilize FireFly's BNA™ technology for brain activity monitoring, comparing results against their FDA-cleared database of 77,000 EEG brain scans. The company reports a successful case study of a patient treated with ACP-01 showing positive results 10 years post-treatment.
Hemostemix (TSXV: HEM) and Firefly Neuroscience (NASDAQ: AIFF) have announced a collaboration to conduct a Phase 1 clinical trial studying ACP-01 as a treatment for vascular dementia. The trial will evaluate brain wave activity in up to 100 patients using Firefly's FDA-Cleared BNA™ platform.
The study will assess patients before treatment and at 3 and 6-month intervals post-treatment. Hemostemix will leverage Firefly's database of 77,000 EEG brain scans across twelve disorders. The trial's primary endpoints include safety assessment, ACP-01 delivery feasibility via intrathecal injection, dosage safety, and tolerability.
Secondary endpoints encompass cognitive functional assessment, clinical dementia rating, quality of life assessment, and MRI analyses of brain volume and blood flow. The exploratory endpoint will use Firefly's BNA™ readout at specified intervals to objectively evaluate ACP-01's efficacy in treating vascular dementia.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) announces the sale of 15 ACP-01 Therapy Convertible Debentures for USD $517,230, pending TSXV Exchange approval. Year-to-date forward sales total CAD $1,149,983, providing non-dilutive working capital.
The company's production capacity is scaling from 20 to 40 treatments per month, and from 40 to 80 treatments monthly. At 20 treatments per month, annual revenue potential is USD $8,880,000 (CAD $12,876,000), with potential to quadruple with one physician performing four blood draws daily.
Each ACP-01 therapy convertible debenture (TCD) is unsecured, convertible into therapy on first-purchased basis, transferable, and earns 6% annual interest payable in shares. TCDs may be listed for trading in the future.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) has secured a strategic perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies for $5,000,000 (twenty million shares), subject to TSXV Exchange acceptance. This breakthrough positions Hemostemix as a leader in the global stem cell market.
The license provides several key advantages:
- Lowest cost of goods sold for allogenic products through automated cell expansion and high yield efficiency
- Strategic protection of autologous stem cell production
- Enhanced scalability of ACP-01
- Reduced facility and labor costs through automated systems
CytoImmune's expertise includes pioneering bioreactor design and AI integration in control systems, with experience in scaling from pilot runs to 20,000-liter industrial capacities. The company achieved the first confirmed stirred tank bioreactor design for allogeneic T cell production.
This strategic move enables Hemostemix to expand clinical trials, accelerate regulatory approvals, pursue global partnerships, and increase profitability through improved margins.
Hemostemix (HMTXF) has secured a perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, positioning itself as a leader in the global stem cell market. The company will pay CytoImmune $5,000,000 (twenty million shares) for the license, subject to TSXV Exchange acceptance.
The strategic advantages include achieving the lowest cost of goods sold for allogenic products, creating a protective barrier around autologous stem cell production, and enhancing ACP-01's scalability. The bioreactor technology offers automated cell expansion, high yield efficiency, reduced facility and labor costs, and economies of scale.
This acquisition enables Hemostemix to expand clinical trials, accelerate regulatory approvals, pursue strategic partnerships, and increase profitability through improved gross margins. The technology leverages CytoImmune's expertise in bioreactor design and AI integration for optimized cell production.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) has issued a clarification regarding its February 10, 2025 announcement about engaging Proconsul Capital for investor relations services. The clarification comes at the request of the Canadian Investment Regulatory Organization (CIRO). The engagement, which began February 6, 2025, involves investor relations and market awareness services with compensation set at $6,000 per month on a month-to-month basis. No stock options have been granted initially, though negotiations for options may occur after three months. The arrangement is subject to TSX Venture Exchange acceptance, and Hemostemix confirms compliance with TSXV Policy 3.4 regarding investor relations activities.
Hemostemix PR Inc. congratulates Luis Muñoz Marín International Airport (SJU) on achieving IATA's CEIV Pharma Certification, a prestigious recognition that places the airport among elite global hubs like Miami and Amsterdam. This certification validates SJU's adherence to the highest standards in handling, storage, and transportation of biologics and pharmaceutical products.
The certification strengthens Puerto Rico's position as a global leader in biologics and pharmaceutical logistics, providing Hemostemix PR Inc. with access to a world-leading certified biologics logistics hub. This infrastructure advancement supports the company's mission by enabling efficient delivery of ACP-01 therapies to patients worldwide, ensuring sensitive biologics are transported with maximum care and compliance.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced the engagement of ProConsul Capital to provide investment marketing consulting services, effective February 6th, 2025. The agreement includes a monthly fee of $6,000 and stock options to be granted to ProConsul, with details to be announced later. The contract operates on a month-to-month renewal basis and can be terminated by either party with 30 days written notice.
Hemostemix (TSXV: HEM) (OTC: HMTXF) announced that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at $0.295 per share, resulting in the issuance of 1,634,466 Common Shares. The transaction is subject to TSXV Exchange approval.
Following the Hemostemix technology transfer presentation at CytoImmune's Innovations & Investment Conference, CytoImmune plans to present Hemostemix's clinical trial results to various medical practitioners in Puerto Rico. The initiative aims to treat no-option patients under a special access program, demonstrate patient improvements, and track healthcare cost reductions. The company highlighted potential revenue opportunities for medical practitioners, stating that implementing four ACP-01 procedures daily could generate additional income of $1,000,000, with each treatment unit priced at $37,000.
Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced its expansion into the Dominican Republic with its ACP-01 therapy. The company has partnered with a team of cardiologists capable of treating 110 patients monthly, who have previously treated 200 ACP-01 recipients. Each ACP unit is priced at USD $37,000.
The treatment's efficacy is documented in a study published in Stem Cell Research and Therapy, involving 54 subjects treated for ischemic and non-ischemic dilated cardiomyopathy. The results showed significant improvements in ejection fraction, with increases of up to 47.1% in dilated cardiomyopathy patients and up to 27% in ischemic cardiomyopathy patients with an ejection fraction of 20% or less.
FAQ
What is the current stock price of Hemostemix (HMTXF)?
What is the market cap of Hemostemix (HMTXF)?
